PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells

Atherosclerosis

Volumn 227, Issue 2, 2013, Pages 297-306

  Levy, Emile ^a,b,c,d   Ouadda, Ali Ben Djoudi ^a   Spahis, Schohraya ^a,b   Sane, Alain Théophile ^a   Garofalo, Carole ^a   Grenier, émilie ^a,b   Emonnot, Lea ^a   Yara, Sabrina ^a,b   Couture, Patrick ^d   Beaulieu, Jean François ^c   Ménard, Daniel ^c   Seidah, Nabil G ^e   Elchebly, Mounib ^a,b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF SHERBROOKE   (Canada)

^d LAVAL UNIVERSITY   (Canada)

^e CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Apo B 48; Cholesterol transporters; Chylomicron; HMG CoA reductase; LDL receptor; Lipid homeostasis

Indexed keywords

APOLIPOPROTEIN B; CD36 ANTIGEN; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; CHYLOMICRON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; NIEMANN PICK C1 LIKE 1 PROTEIN; PROPROTEIN CONVERTASE SUBTILLISIN KEXIN TYPE 9; PROTEIN; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; BASOLATERAL MEMBRANE; BIOGENESIS; CELL STRAIN CACO 2; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; ENZYME ACTIVITY; GAIN OF FUNCTION MUTATION; HOMEOSTASIS; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INTESTINE EPITHELIUM CELL; LIPID TRANSPORT; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BIOLOGICAL TRANSPORT; CACO-2 CELLS; CHOLESTEROL; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEK293 CELLS; HEP G2 CELLS; HOMEOSTASIS; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; INTESTINES; LIPID METABOLISM; LIPOPROTEINS; PROPROTEIN CONVERTASES; RECEPTORS, LDL; SERINE ENDOPEPTIDASES;

EID: 84875055214     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.01.023     Document Type: Article

References (43)

1. Seidah N.G., Benjannet S., Wickham L., et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A 2003, 100:928-933.
2. Maxwell K.N., Breslow J.L. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proc Natl Acad Sci U S A 2004, 101:7100-7105.
3. Seidah N.G., Prat A. The proprotein convertases are potential targets in the treatment of dyslipidemia. J Mol Med 2007, 85:685-696.
4. Attie A.D., Seidah N.G. Dual regulation of the LDL receptor-some clarity and new questions. Cell Metab 2005, 1:290-292.
5. Li J., Tumanut C., Gavigan J.A., et al. Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity. Biochem J 2007, 406:203-207.
6. Clark L.T. Optimizing lipid lowering in patients at risk. Clin Cardiol 2004, 27:III22-III26.
7. Lambert G. Unravelling the functional significance of PCSK9. Curr Opin Lipidol 2007, 18:304-309.
8. Turley S.D., Dietschy J.M. Sterol absorption by the small intestine. Curr Opin Lipidol 2003, 14:233-240.
9. Turley S.D. Cholesterol metabolism and therapeutic targets: rationale for targeting multiple metabolic pathways. Clin Cardiol 2004, 27:III16-III21.
10. Thomson A.B., Dietschy J.M. Intestinal lipid absorption: major extracellular and intracellular events. Physiology of the gastrointestinal tract 1981, 1147-1220. Raven, New York. L.R. Johnson (Ed.).
11. Turley S.D., Dietschy J.M. Cholesterol metabolism and excretion. The liver: biology and pathobiology 1982, 467-492. Raven Press, New York. I. Arias, H. Popper, D. Schachter, D.A. Shafritz (Eds.).
12. Spady D.K., Bilheimer D.W., Dietschy J.M. Rates of receptor-dependent and -independent low density lipoprotein uptake in the hamster. Proc Natl Acad Sci U S A 1983, 80:3499-3503.
13. Leblond F., Seidah N.G., Precourt L.P., et al. Regulation of the proprotein convertase subtilisin/kexin type 9 in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol 2009, 296:G805-G815.
14. Benjannet S., Rhainds D., Hamelin J., et al. The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications. J Biol Chem 2006, 281:30561-30572.
15. Poirier S., Mayer G., Benjannet S., et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem 2008, 283:2363-2372.
16. Grenier E., Garofalo C., Delvin E., Levy E. Modulatory role of PYY in transport and metabolism of cholesterol in intestinal epithelial cells. PLoS One 2012, 7:e40992.
17. Levy E., Menard D., Suc I., et al. Ontogeny, immunolocalisation, distribution and function of SR-BI in the human intestine. J Cell Sci 2004, 117:327-337.
18. Levy E., Garofalo C., Rouleau T., et al. Impact of essential fatty acid deficiency on hepatic sterol metabolism in rats. Hepatology 1996, 23:848-857.
19. Marcil V., Delvin E., Seidman E., et al. Modulation of lipid synthesis, apolipoprotein biogenesis, and lipoprotein assembly by butyrate. Am J Physiol Gastrointest Liver Physiol 2002, 283:G340-G346.
20. Courtois F., Suc I., Garofalo C., et al. Iron-ascorbate alters the efficiency of Caco-2 cells to assemble and secrete lipoproteins. Am J Physiol Gastrointest Liver Physiol 2000, 279:G12-G19.
21. Levy E., Loirdighi N., Thibault L., et al. Lipid processing and lipoprotein synthesis by the developing human fetal colon. Am J Physiol 1996, 270:G813-G820.
22. Levy E., Beaulieu J.F., Delvin E., et al. Human crypt intestinal epithelial cells are capable of lipid production, apolipoprotein synthesis, and lipoprotein assembly. J Lipid Res 2000, 41:12-22.
23. Levy E., Menard D., Delvin E., et al. The polymorphism at codon 54 of the FABP2 gene increases fat absorption in human intestinal explants. J Biol Chem 2001, 276:39679-39684.
24. Grenier E., Maupas F.S., Beaulieu J.F., et al. Effect of retinoic acid on cell proliferation and differentiation as well as on lipid synthesis, lipoprotein secretion, and apolipoprotein biogenesis. Am J Physiol Gastrointest Liver Physiol 2007, 293:G1178-G1189.
25. Montoudis A., Seidman E., Boudreau F., et al. Intestinal fatty acid binding protein regulates mitochondrion beta -oxidation and cholesterol uptake. J Lipid Res 2008.
26. Fong L.G., Bonney E., Kosek J.C., Cooper A.D. Immunohistochemical localization of low density lipoprotein receptors in adrenal gland, liver, and intestine. J Clin Invest 1989, 84:847-856.
27. Qian Y.W., Schmidt R.J., Zhang Y., et al. Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis. J Lipid Res 2007, 48:1488-1498.
28. Hori M., Satoh M., Furukawa K., et al. Acyl-coenzyme A: cholesterol acyltransferase-2 (ACAT-2) is responsible for elevated intestinal ACAT activity in diabetic rats. Arterioscler Thromb Vasc Biol 2004, 24:1689-1695.
29. Pathak R.K., Yokode M., Hammer R.E., et al. Tissue-specific sorting of the human LDL receptor in polarized epithelia of transgenic mice. J Cell Biol 1990, 111:347-359.
30. Davignon J., Dubuc G. Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels. Trans Am Clin Climatol Assoc 2009, 120:163-173.
31. Kam N.T., Albright E., Mathur S.N., Field F.J. Inhibition of acylcoenzyme A: cholesterol acyltransferase activity in CaCo-2 cells results in intracellular triglyceride accumulation. J Lipid Res 1989, 30:371-377.
32. Herbert B., Patel D., Waddington S.N., et al. Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control. Arterioscler Thromb Vasc Biol 2010, 30:1333-1339.
33. Roubtsova A., Munkonda M.N., Awan Z., et al. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol 2011, 31:785-791.
34. Ai D., Chen C., Han S., et al. Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice. J Clin Invest 2012, 122:1262-1270.
35. Duan Y., Chen Y., Hu W., et al. Peroxisome proliferator-activated receptor gamma activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression. J Biol Chem 2012, 287:23667-23677.
36. Dubuc G., Chamberland A., Wassef H., et al. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2004, 24:1454-1459.
37. Jeong H.J., Lee H.S., Kim K.S., et al. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. J Lipid Res 2008, 49:399-409.
38. Lan H., Pang L., Smith M.M., et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells. J Cell Physiol 2010, 224:273-281.
39. Naoumova R.P., Tosi I., Patel D., et al. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-term follow-up and treatment response. Arterioscler Thromb Vasc Biol 2005, 25:2654-2660.
40. Baass A., Dubuc G., Tremblay M., et al. Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. Clin Chem 2009, 55:1637-1645.
41. Lakoski S.G., Lagace T.A., Cohen J.C., et al. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab 2009, 94:2537-2543.
42. Le M.C., Kourimate S., Langhi C., et al. Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler Thromb Vasc Biol 2009, 29:684-690.
43. Banach M., Rizzo M., Obradovic M., et al. PCSK9 inhibition - a novel mechanism to treat lipid disorders?. Curr Pharm Des 2012.